10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders

Intravenous immunoglobulins have been used to treat autoimmune disorders (ADs) for over 50 years. The etiologies of various ADs are not fully understood and although intravenous immunoglobulin treatment has proved its immunomodulatory properties, the roles of proposed mechanisms of action also remai...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 8; no. 8; pp. 923 - 940
Main Authors Nikolov, Nikolai, Reisinger, Jürgen, Schwarz, Hans P
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.07.2016
Subjects
Alzheimer's disease
Animals
Antigens
Arthritis
Autoimmune diseases
Autoimmune Diseases - immunology
Autoimmune Diseases - therapy
Chemokines
Clinical trials
Clinical Trials as Topic
Cytokines
Demyelination
Guillain-Barre syndrome
Humans
Idiopathic thrombocytopenic purpura
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Immunomodulation
Immunosuppressive Agents - therapeutic use
Immunotherapy - methods
Inflammation
Inflammatory diseases
Intravenous administration
Kawasaki disease
Lupus
Mucocutaneous lymph node syndrome
Nervous System Diseases - immunology
Nervous System Diseases - therapy
Patients
Polyneuropathy
Population studies
Progressive motor neuropathy
Thrombocytopenic purpura
United States > US
autoimmune diseases
intravenous immunoglobulin
KIOVIG
GAMMAGARD Liquid
Online AccessGet full text

Cover

More Information
Summary:Intravenous immunoglobulins have been used to treat autoimmune disorders (ADs) for over 50 years. The etiologies of various ADs are not fully understood and although intravenous immunoglobulin treatment has proved its immunomodulatory properties, the roles of proposed mechanisms of action also remain a matter of speculation. A systemic search of the literature regarding KIOVIG(®) (Baxalta US, Inc., MA, USA) use in clinical trials on patients with ADs and a detailed review of retrieved articles revealed eight relevant publications. These articles reported KIOVIG use in multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome and other autoimmune and neurologic disorders and showed that KIOVIG is an effective, safe and well-tolerated treatment in the studied populations. Nevertheless, further studies on larger patient cohorts are needed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2016-0041